Evidence map›Paper›PMID 36177003›Full record

ArticleFrontiers in immunology2022

Novel macrophage-related gene prognostic index for glioblastoma associated with M2 macrophages and T cell dysfunction.

Hang Ji, Zhihui Liu, Fang Wang, Haogeng Sun, Nan Wang, Yi Liu, Shaoshan Hu, Chao You

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Establishment of molecular subtypes and prognostic models for glioblastoma based on non-apoptotic regulatory cell death genes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Hang JiDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Zhihui LiuCancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Fang WangCancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Haogeng SunDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Nan WangCancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Yi LiuDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Shaoshan HuCancer Center, Department of Neurosurgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Chao YouDepartment of Neurosurgery, West China Hospital, Sichuan University, Chengdu, China.
Zhejiang Provincial People's Hospital · CNHangzhou Medical College · CNSichuan University · CNWest China Hospital of Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aims to construct a Macrophage-Related Gene Prognostic Index (MRGPI) for glioblastoma (GBM) and explore the underlying molecular, metabolic, and immunological features. Based on the GBM dataset from The Cancer Genome Atlas (n = 156), 13 macrophage-related hub genes were identified by weighted gene co-expression network (WGCNA) analysis. 5 prognostic genes screened by Kaplan-Meire (K-M) analysis and Cox regression model were used to construct the MRGPI, including GPR84, NCF2, HK3, LILRB2, and CCL18. Multivariate Cox regression analysis found that the MRGPI was an independent risk factor (HR = 2.81, CI95: 1.13-6.98, p = 0.026), leading to an unfavorable outcome for the MRGPI-high group, which was further validated by 4 validation GBM cohorts (n = 728). Thereafter, the molecular, metabolic, and immune features and the clinical implications of the MRGPI-based groups were comprehensively characterized. Gene set enrichment analysis (GSEA) found that immune-related pathways, including inflammatory and adaptive immune response, and activated eicosanoid metabolic pathways were enriched in the MRGPI-high group. Besides, genes constituting the MRGPI was primarily expressed by monocytes and macrophages at single-cell scope and was associated with the alternative activation of macrophages. Moreover, correlation analysis and receiver operating characteristic (ROC) curves revealed the relevance between the MRGPI with the expression of immune checkpoints and T cell dysfunction. Thus, the responsiveness of samples in the MRGPI-high group to immune checkpoint inhibitors (ICI) was detected by algorithms, including Tumor Immune Dysfunction and Exclusion (TIDE) and Submap. In contrast, the MRGPI-low group had favorable outcome, was less immune active and insensitive to ICI. Together, we have developed a promising biomarker to classify the prognosis, metabolic and immune features for GBM, and provide references for facilitating the personalized application of ICI in GBM.

Indexed as

GlioblastomaHumansImmune Checkpoint InhibitorsMacrophagesPrognosisT-LymphocytesImmune Checkpoint Inhibitorseicosanoid metabolismglioblastomaimmune checkpoint inhibitiontumor-associated macrophagetumor microenvironment

Identifiers

PMID36177003
PMCPMC9513135
OpenAlexW4295847355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.